Welcome to BioSeeker Group!

Triple Analysis: Colorectal Cancer, Cancer Vaccines and Peptides

Additional Information

Published Date Mar 19, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3076
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Colorectal Cancer, Cancer Vaccines and Peptides in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Colorectal Cancer), one mechanism/target/effect area (Cancer Vaccines) and one compound specific area (Peptides).

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Colorectal Cancer, Cancer Vaccines and Peptides.

    To find out more about Triple Analysis: Colorectal Cancer, Cancer Vaccines and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Colorectal Cancer, Cancer Vaccines and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Colorectal Cancer), one mechanism/target/effect area (Cancer Vaccines) and one compound specific area (Peptides). Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Colorectal Cancer
The colorectal cancer report part comprises defined and up to date development strategies for 347 colorectal cancer drugs within the portfolio of 182 investigators, from Ceased to Marketed. This part extensively analyses their 210 identified drug targets, organized into 205 drug target strategies, and assesses them in eight different compound strategies in colorectal cancer.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Colorectal Cancer Pipeline: From Research and Development to Market

Part II: Cancer Vaccines
The cancer vaccine drug report part comprises defined and up to date development strategies for 196 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 137 identified drug targets, organized into 114 drug target strategies, and assesses them in 52 cancer indications.
This part is based on the following publication:
Cancer Vaccines: From First-in-Class to Best-in-Class?

Part III: Peptides
The peptide drug report part comprises defined and up to date development strategies for 171 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 132 identified drug targets, organized into 109 drug target strategies, and assesses them in 62 cancer indications.
This part is based on the following publication:
Cancer Peptides: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Colorectal Cancer
5.1 The Scope of this Report 28
6 Consider the Therapeutic Target Among Colorectal Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (210 Drug Targets) 32-451
7 Emerging New Products to Established Ones: Drug Target Strategies of Colorectal Cancer Drugs by their Highest Stage of Development (205 Drug Target Strategies and 347 Colorectal Cancer Drugs) 452-699
8 Compound Strategies at Work: Competitive Benchmarking of Colorectal Cancer Drugs by Compound Strategy (8 Compound Strategies) 700-745
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Colorectal Cancer Drug Pipeline by Investigator (182 Companies) 746-1,039
10 Disclaimer 1040
11 Drug Index 1041
12 Company Index 1050
Figures: Includes 6 Figures
Tables: Includes 242 Tables
Total Number of Pages: 1,056

Part II: Cancer Vaccines
5.1 The Scope of this Report 28
6 Consider the Therapeutic Target Among Cancer Vaccine Drugs for the Highest Therapeutic Outcome and Return on Investment (137 Drug Targets) 32-245
7 First-in-Class and Me-too Analysis of Cancer Vaccine Drugs (114 Drug Target Strategies and 196 Drugs) 246-262
8 Is First-in-Class the Best-in-Class? 263-386
9 Compound Strategies at Work: Competitive Benchmarking of Cancer Vaccine Drugs by Compound Strategy (7 Compound Strategies) 387-413
10 The Competition Through Close Mechanistic Approximation of Cancer Vaccine Drugs 414-416
11 Selecting Indications for Cancer Vaccine Drugs (52 Cancer Indications) 417-492
12 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Vaccine Drug Pipeline by Company (114 Companies and 196 Drugs) 493-993
13 Disclaimer 994
Figures: Includes 5 Figures
Tables: Includes 239 Tables
Total Number of Pages: 1,007

Part III: Peptides
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Peptide Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (132 Drug Targets) 31-252
7 First-in-Class and Me-too Analysis of Peptide Drugs in Cancer (109 Drug Target Strategies and 171 Drugs) 253-267
8 Is First-in-Class the Best-in-Class? (109 Drug Target Strategies and 171 Drugs) 268-387
9 The Competition through Close Mechanistic Approximation of Peptide Drugs in Cancer 388
10 Selecting Indication for Peptide Drugs in Oncology ( 62 Cancer Indications) 391-475
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Peptide Drug Pipeline by Investigator (114 Investigators and 171 Drugs) 476-1001
12 Disclaimer 1002
Figures: Includes 5 Figures
Tables: Includes 232 Tables
Total Number of Pages: 1,013

This Report Includes the Following Companies:
7TM Pharma
Abbott
AC Immune
Acceleron Pharma
Adaptimmune
Adherex
Advaxis
AEterna Zentaris
Affimed Therapeutics
Affymax
Agenus
Aida Pharmaceuticals
Aileron Therapeutics
Alchemia
Alethia Biotherapeutics
Allos Therapeutics
Allostera
Allosterix
Alnylam
AlphaVax
Alseres Pharmaceuticals
Ambrilia Biopharma
Amgen
Anavex Life Sciences
Anchor Therapeutics
AngioChem
Angstrom Pharmaceuticals
Antisense Pharma
Anza Therapeutics
AplaGen Biopharmaceuticals
ApopLogic Pharmaceuticals
Apotex
Ardana
Argos Therapeutics
Ariad
ArQule
Array BioPharma
Astellas
AstraZeneca
Attenuon
AVEO
AVI BioPharma
Bavarian Nordic
Baxter International
Bayer
Bellicum Pharmaceuticals
Betapharma
BioAlliance Pharma
Biocompatibles
Biogen Idec
Biokine Therapeutics
BioNTech
BioNumerik
BioSante
Biostar
BioVex
Boehringer Ingelheim
BreakThrough Therapeutics
Bristol-Myers Squibb
BTG
Camurus
Can-Fite BioPharma
CanBas
Cancer Advances
Cancer Innovations
Cancer Research Technology
CDG Therapeutics
Celator Pharmaceuticals
Celecure
Celera
Celgene
Cell Therapeutics
Celldex Therapeutics
Cellmid
Celsion
Celtic Pharma
Center of Molecular Immunology
CG Therapeutics
ChemGenex Pharmaceuticals
Chemokine Therapeutics
Chiasma
Choongwae
Circadian Technologies
Clavis Pharma
Cleveland BioLabs
Clinuvel
Compugen
Cosmo Pharmaceuticals
CreaGene
CSL
CuraGen
Curaxis
CureTech
CureVac
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytokinetics
Daiichi Sankyo
Dainippon Sumitomo Pharma
Debiopharm
Deciphera Pharmaceuticals
Dendreon
DeveloGen
Digna Biotech
Dongkook Pharm
Dynavax Technologies
EGEN Inc
Eisai
Eli Lilly
Endo Pharmaceuticals
Enkam Pharmaceuticals
EntreMed
Enzon
Epeius Biotechnologies
EpiCept
Esperance Pharmaceuticals
Etubics
Exelixis
FasTrack Pharmaceuticals
Formula Pharmaceuticals
Galena Biopharma
Generex
Genmab
GenOdyssee Pharmaceuticals
GENova Biotherapeutics
Genovax
Genta
Genticel
GenVec
Genzyme
Geron
Gilead Sciences
GlaxoSmithKline
Glide Pharma
Gliknik
GlobeImmune
GlycoGenesys
GP Pharm
Gradalis
Green Cross
Gryphon Therapeutics
Heat Biologics
Heidelberg Pharma
Hemispherx Biopharma
Hoffmann-La Roche
Human Genome Sciences
Ichor Medical Systems
Idera Pharmaceuticals
IkerChem
immatics biotechnologies
ImmunoCellular Therapeutics
Immunocore
ImmunoFrontier
Immunomedics
Immunotope
Immunovaccine
ImmuPharma
Incyte Corporation
InNexus Biotechnology
Innovive
Inovio
Insys Therapeutics
Intracel
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Ivy Medical Chemicals
Jennerex Biotherapeutics
Johnson & Johnson
KAEL-GemVax
Karyon-CTT
Kiadis
Kirax
Kyowa Hakko Kirin
Labopharm
Lee’s Pharmaceutical
Leo
Lipotek
Lorus Therapeutics
MacroGenics
Mannkind
Marillion Pharmaceuticals
MBiotec
Meda
MediGene
Mediolanum
Menarini
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MethylGene
Micromet
Mitsubishi Tanabe Pharma
MolMed
Mologen
Momotaro-Gene
Nektar Therapeutics
Nemod Biotherapeutics
Neovacs
Nerviano Medical Sciences
Neurobiological Technologies
NicOx
Nidus Laboratories
NIH
Nippon Kayaku
Non-industrial source
Northwest Biotherapeutics
Novartis
NovaRx
NPS Pharmaceuticals
Nycomed Pharma
OncoGenex Pharmaceuticals
OncoMed
OncoMune
Onconova
OncoTherapy Science
Oncothyreon
Oncovir
Oncozyme Pharma
Onyvax
Orca Therapeutics
Orchestra Therapeutics
Oxford BioMedica
OXiGENE
PanaGin
Pepscan Therapeutics
Peptagen
PepTx
Pfizer
Pharmaclon
PharmaForm
PharmaGap
PharmaMar
Pharmexa
Philogen
Pierre Fabre
Plexxikon
POZEN
Pro-Pharmaceuticals
Progenics Pharmaceuticals
Protagonist
Protherics
Q Chip
QLT
Radient Pharmaceuticals
Raptor Pharmaceutical
Receptor BioLogix
Regeneron
responsif
Rigel
Sanofi
Sanofi-Aventis
Santaris Pharma
Sarepta Therapeutics
Sareum
Scancell
SciClone Pharmaceuticals
Serometrix
Shionogi
Shire
Sigma-Tau
Simcere Pharmaceuticals
Soligenix
Spectrum Pharmaceuticals
Spirogen
SRI International
SuperGen
Supratek Pharma
SynDevRx
Synta Pharmaceuticals
Tactic Pharma
Taiho
Takeda
Talon Therapeutics
TapImmune
Targepeutics
Tau Therapeutics
Taxolog
Telik
Thallion Pharmaceuticals
The Genetics Company
Therion Biologics
Theryte
ThromboGenics
Titan Pharmaceuticals
TopoTarget
Transgene
Trion Pharma
Unigene
United Biomedical
Vaccinex
Vaxil BioTherapeutics
Vaximm
Vaxon Biotech
Vectura
Vertex Pharmaceuticals
Vical
Wilex
VioQuest Pharmaceuticals
Viragen
Viralytics
Virionics
ViroMed
Wyeth
Xerion
Xigen
Yakult Honsha
YM BioSciences
Zelos Therapeutics
Zensun
Zydus Cadila
A Shortlist of Drugs Included are:
A6
abagovomab
abarelix
ABT-510
ADXS11-001
AE-37
AEZS-108
afamelanotide
aflibercept
AGS-003
angiopep+paclitaxel
Angiozyme
ANZ-207
astuprotimut-r
Auto TAG vaccine
AVX-701
belagenpumatucel-L
bevacizumab
BP-GMAX-CD1
brivanib alaninate
BV-NSCLC-001
capecitabine
catumaxomab
CB-10-01
CBP-501
CDX-1307
cediranib
cetuximab
CG-201
corticorelin acetate
CreaVax-PC
CV-9103
CV-9201
CVac
DCVax-prostate
deslorelin
doxifluridine
E-75
emepepimut-S
EP-100
everolimus
FPI-01
GI-4000
goserelin
GSK-2130579A
GV-1001
GVAX
GVX-3322
GX-301
Her-2/Neu peptides
Hi-8 MEL
histrelin
HS-110
ICT-107
imMucin
IMO-2055
interferon gamma
interleukin-12
IPP-204106
irinotecan bead
irinotecan hydrochloride
ISA-P53-01
JX-594
kahalalide F
lanreotide
leukemia vaccine
leuprolide
leuprolide acetate
leuprorelin
MDX-1379
MGN-1601
MGN-1703
MVA-BN Her-2 vaccine
NAFB001
netupitant
octreotide
octreotide, LAR
OncoVAX
Onyvax-105
OTS-102
ozarelix
p.DOM-WT1-37/p.DOM-WT1-126 DNA
panitumumab
pasireotide
pasireotide LAR
perifosine
plitidepsin
poly-ICLC
polyclonal antibody stimulator
PROSTVAC
PSMA ADC
raltitrexed
ramucirumab
regorafenib
Reximmune-C
rindopepimut
rintatolimod
romurtide
S-488410
SCIB-1
sipuleucel-T
sotatercept
Survivac
tegafur + uracil
tegafur + uracil + leucovorin
TG-4010
thymalfasin
tipapkinogene sovacivec
TM-30339
TroVax
TS-1
vapreotide, immediate-release
velimogene aliplasmid
verpasep caltespen
vitespen
VX-001

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Colorectal Cancer, Cancer Vaccines and Peptides.
    To find out more about Triple Analysis: Colorectal Cancer, Cancer Vaccines and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Colorectal Cancer, Cancer Vaccines and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Pancreatic Cancer, Prostate Cancer and Cancer Vaccines
This triple analysis focuses on cancer drug development strategies in both Pancreatic Cancer and Prostate Cancer and by the mechanism/target/effect of Cancer Vaccines. Learn More


Triple Analysis: Melanoma, Apoptosis and Angiogenesis
This triple analysis focuses on cancer drug development strategies in Melanoma and by the two mechanism/target/effect areas of Apoptosis and Angiogenesis. Learn More

Other selected research from the 'Oncology' category:


Strategic Outlook on Protein Kinase Inhibitors in Oncology
A strategic outlook on protein kinase inhibitors in oncology. Including targets, indictions and competitive assessment. Learn More


Cancer Vaccines: From First-in-Class to Best-in-Class?
In-depth pipeline analytics of cancer vaccine drugs showing you where the competition is, what is first-in-class and is first-in-class the best-in-class?, Indication expansion opportunities and much more Learn More